Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 114400.0
(-4.75%)
KRW 114400.0
(-4.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 94.48 Billion KRW | 7.48% |
| 2022 | 87.9 Billion KRW | 8.2% |
| 2021 | 81.24 Billion KRW | -12.2% |
| 2020 | 92.53 Billion KRW | -15.46% |
| 2019 | 109.46 Billion KRW | 32.46% |
| 2018 | 82.63 Billion KRW | -1.93% |
| 2017 | 84.26 Billion KRW | 7.2% |
| 2016 | 78.61 Billion KRW | 9.6% |
| 2015 | 71.72 Billion KRW | 10.25% |
| 2014 | 65.05 Billion KRW | 15.31% |
| 2013 | 56.41 Billion KRW | 48.83% |
| 2012 | 37.9 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 25.04 Billion KRW | 9.69% |
| 2024 Q1 | 23.37 Billion KRW | -3.86% |
| 2023 Q3 | 23.98 Billion KRW | 0.05% |
| 2023 Q4 | 24.31 Billion KRW | 1.36% |
| 2023 FY | 94.48 Billion KRW | 7.48% |
| 2023 Q1 | 22.21 Billion KRW | 4.55% |
| 2023 Q2 | 23.97 Billion KRW | 7.91% |
| 2022 FY | 87.9 Billion KRW | 8.2% |
| 2022 Q1 | 21.35 Billion KRW | 15.94% |
| 2022 Q2 | 22.68 Billion KRW | 6.24% |
| 2022 Q3 | 22.62 Billion KRW | -0.24% |
| 2022 Q4 | 21.25 Billion KRW | -6.08% |
| 2021 Q3 | 22.68 Billion KRW | 9.08% |
| 2021 Q1 | 19.34 Billion KRW | -2.2% |
| 2021 Q2 | 20.79 Billion KRW | 7.48% |
| 2021 Q4 | 18.41 Billion KRW | -18.83% |
| 2021 FY | 81.24 Billion KRW | -12.2% |
| 2020 Q2 | 25.69 Billion KRW | 7.19% |
| 2020 FY | 92.53 Billion KRW | -15.46% |
| 2020 Q4 | 19.78 Billion KRW | -18.69% |
| 2020 Q3 | 24.33 Billion KRW | -5.3% |
| 2020 Q1 | 23.97 Billion KRW | -0.72% |
| 2019 Q2 | 27.35 Billion KRW | 10.31% |
| 2019 Q1 | 24.79 Billion KRW | 37.67% |
| 2019 FY | 109.46 Billion KRW | 32.46% |
| 2019 Q4 | 24.14 Billion KRW | -29.39% |
| 2019 Q3 | 34.19 Billion KRW | 25.0% |
| 2018 Q2 | 22.39 Billion KRW | 8.08% |
| 2018 Q3 | 21.83 Billion KRW | -2.5% |
| 2018 Q4 | 18.01 Billion KRW | -17.51% |
| 2018 FY | 82.63 Billion KRW | -1.93% |
| 2018 Q1 | 20.72 Billion KRW | 5.33% |
| 2017 Q1 | 21.46 Billion KRW | 5.07% |
| 2017 FY | 84.26 Billion KRW | 7.2% |
| 2017 Q4 | 19.67 Billion KRW | -14.79% |
| 2017 Q2 | 20.28 Billion KRW | -5.49% |
| 2017 Q3 | 23.08 Billion KRW | 13.83% |
| 2016 FY | 78.61 Billion KRW | 9.6% |
| 2016 Q3 | 19.98 Billion KRW | 1.51% |
| 2016 Q4 | 20.42 Billion KRW | 2.18% |
| 2016 Q2 | 19.69 Billion KRW | 4.75% |
| 2016 Q1 | 18.79 Billion KRW | -1.77% |
| 2015 FY | 71.72 Billion KRW | 10.25% |
| 2015 Q3 | 18.89 Billion KRW | 10.15% |
| 2015 Q4 | 19.13 Billion KRW | 1.27% |
| 2015 Q2 | 17.15 Billion KRW | 3.01% |
| 2015 Q1 | 16.65 Billion KRW | -0.26% |
| 2014 Q2 | 15.83 Billion KRW | -2.59% |
| 2014 Q1 | 16.25 Billion KRW | 10.7% |
| 2014 FY | 65.05 Billion KRW | 15.31% |
| 2014 Q4 | 16.69 Billion KRW | 2.62% |
| 2014 Q3 | 16.27 Billion KRW | 2.75% |
| 2013 Q2 | 13.78 Billion KRW | 7.45% |
| 2013 Q3 | 15.12 Billion KRW | 9.73% |
| 2013 Q1 | 12.82 Billion KRW | 0.0% |
| 2013 Q4 | 14.68 Billion KRW | -2.91% |
| 2013 FY | 56.41 Billion KRW | 48.83% |
| 2012 FY | 37.9 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 5.04 Billion KRW | -1774.297% |
| ST Pharm Co.,Ltd. | 106.62 Billion KRW | 11.387% |
| ABL Bio Inc. | 65.5 Billion KRW | -44.253% |
| Cellid, Co., Ltd. | -2.66 Billion KRW | 3647.357% |